HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 62305

HXB2 Location  gp160(61-69)   gp160 Epitope Map
View variants at this location
Epitope YETEVHNVW   Epitope Alignment
Variants
YkTEVHNVW   observed variant
YEkEVHNVW   observed variant
YgTEVHNVW   observed variant
YqTEVHNVW   observed variant
YEaEVHNVW   observed variant
YEaEVHsVW   observed variant
YETgiHNVW   observed variant
YETEaHNVW   observed variant; replicative capacity is not abrogated; susceptible form
YdTEaHNVW   escape documented in this paper; replicative capacity/ fitness enhanced; observed variant
hETEaHNVW   observed variant
YdTEVHNVW   escape documented in this paper; replicative capacity/ fitness enhanced; observed variant
YdiEVHNVW   escape documented in this paper; observed variant
Epitope Name YW9
Species (MHC/HLA human(B*18)

Variant Details

Showing all: 12 variant(s).


Variant ID.  4408
Epitope Seq.  YETEVHNVW
Variant Seq.  YkTEVHNVW
Mutations E/K
Epitope Location E2K
HXB2 Location E62K
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Longitudinal study, Other, Sequence
Note Mutant YkTEVHNVW was seen in patient PIC1362 from 50-190 DPS (days post symptoms).


Variant ID.  4409
Epitope Seq.  YETEVHNVW
Variant Seq.  YEkEVHNVW
Mutations T/K
Epitope Location T3K
HXB2 Location T63K
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Longitudinal study, Other, Sequence
Note Mutant, YEkEVHNVW, was seen in patient PIC1362 from 155-190 DPS (days post symptoms).


Variant ID.  4410
Epitope Seq.  YETEVHNVW
Variant Seq.  YgTEVHNVW
Mutations E/G
Epitope Location E2G
HXB2 Location E62G
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Longitudinal study, Other, Sequence
Note Mutant, YgTEVHNVW, was seen in patient PIC1362 at 155 DPS (days post symptoms).


Variant ID.  4411
Epitope Seq.  YETEVHNVW
Variant Seq.  YqTEVHNVW
Mutations E/Q
Epitope Location E2Q
HXB2 Location E62Q
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Longitudinal study, Other, Sequence
Note Mutant YqTEVHNVW was seen in patient PIC1362 only at 155 DPS (days post symptoms).


Variant ID.  4412
Epitope Seq.  YETEVHNVW
Variant Seq.  YEaEVHNVW
Mutations T/A
Epitope Location T3A
HXB2 Location T63A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Longitudinal study, Other, Sequence
Note Mutant YYEaEVHNVW was seen in patient PIC1362 only at 155 DPS (days post symptoms).


Variant ID.  4413
Epitope Seq.  YETEVHNVW
Variant Seq.  YEaEVHsVW
Mutations T/A N/S
Epitope Location T3A N7S
HXB2 Location T63A N67S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Longitudinal study, Other, Sequence
Note Mutant YYEaEVHsVW was seen in patient PIC1362 only at 155 DPS (days post symptoms).


Variant ID.  4414
Epitope Seq.  YETEVHNVW
Variant Seq.  YETgiHNVW
Mutations E/G V/I
Epitope Location E4G V5I
HXB2 Location E64G V65I
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Longitudinal study, Other, Sequence
Note Mutant YETgiHNVW was seen in patient PIC1362 only at 190 DPS (days post symptoms).


Variant ID.  4415
Epitope Seq.  YETEVHNVW
Variant Seq.  YETEaHNVW
Mutations V/A
Epitope Location V5A
HXB2 Location V65A
Mutation Type OV: observed variant
RCOK: replicative capacity is not abrogated
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, Longitudinal study, Other, Relative replication capacity assay, Sequence
Note Mutant YETEaHNVW was seen in patient PIC1362 from 50-190 DPS (days post symptoms). This fitness neutral V65A mutant showed enhanced CTL recognition.


Variant ID.  4416
Epitope Seq.  YETEVHNVW
Variant Seq.  YdTEaHNVW
Mutations E/D V/A
Epitope Location E2D V5A
HXB2 Location E62D V65A
Mutation Type E: escape documented in this paper
F: replicative capacity/ fitness enhanced
OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Longitudinal study, Other, Relative replication capacity assay, Sequence
Note Mutant YdTEaHNVW was seen in patient PIC1362 from 344-826 DPS (days post symptoms), it had become the sole form of the epitope by 769 DPI. This linked dual mutant, E62D/V65A, encoded a fitter virus that was resistant to CTL recognition and MHC display; resisting CTL pressure.


Variant ID.  4417
Epitope Seq.  YETEVHNVW
Variant Seq.  hETEaHNVW
Mutations Y/H V/A
Epitope Location Y1H V5A
HXB2 Location Y61H V65A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Longitudinal study, Other, Sequence
Note Mutant YdTEaHNVW was seen in patient PIC1362 at 344 DPS (days post symptoms).


Variant ID.  4418
Epitope Seq.  YETEVHNVW
Variant Seq.  YdTEVHNVW
Mutations E/D
Epitope Location E2D
HXB2 Location E62D
Mutation Type E: escape documented in this paper
F: replicative capacity/ fitness enhanced
OV: observed variant
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, Longitudinal study, Other, Relative replication capacity assay, Sequence
Note Mutant YdTEVHNVW was seen in patient PIC1362 from 155-769 DPS (days post symptoms). This E62D mutant had increased fitness but displayed peptides modestly and was resistant to CTL recognition.


Variant ID.  4419
Epitope Seq.  YETEVHNVW
Variant Seq.  YdiEVHNVW
Mutations E/D T/I
Epitope Location E2D T3I
HXB2 Location E62D T63I
Mutation Type E: escape documented in this paper
OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Longitudinal study, Other, Sequence
Note Mutant YdiEVHNVW was seen in patient PIC1362 at only 344 DPS (days post symptoms).

References

Troyer2009 Ryan M. Troyer, John McNevin, Yi Liu, Shao Chong Zhang, Randall W. Krizan, Awet Abraha, Denis M. Tebit, Hong Zhao, Santiago Avila, Michael A. Lobritz, M. Juliana McElrath, Sylvie Le Gall, James I. Mullins, and Eric J. Arts. Variable Fitness Impact of HIV-1 Escape Mutations to Cytotoxic T Lymphocyte (CTL) Response. PLoS Pathog., 5(4):e1000365, Apr 2009. PubMed ID: 19343217. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health